The influence of OKT3 therapy on hepatocellular carcinoma recurrence following liver transplantation
Article first published online: 20 DEC 2009
© 2009 John Wiley & Sons A/S
Volume 24, Issue 4, pages E103–E108, July/August 2010
How to Cite
Zimmerman, M. A., Kelly, M. A., Campsen, J., Mandell, M. S., Wachs, M., Bak, T., Skibba, A., Lancaster, B. and Kam, I. (2010), The influence of OKT3 therapy on hepatocellular carcinoma recurrence following liver transplantation. Clinical Transplantation, 24: E103–E108. doi: 10.1111/j.1399-0012.2009.01179.x
- Issue published online: 12 AUG 2010
- Article first published online: 20 DEC 2009
- Accepted for publication 9 October 2009
- hepatocellular carcinoma;
Zimmerman MA, Kelly MA, Campsen J, Mandell MS, Wachs M, Bak T, Skibba A, Lancaster B, Kam I. The influence of OKT3 therapy on hepatocellular carcinoma recurrence following liver transplantation. Clin Transplant 2010: 24: E103–E108. © 2009 John Wiley & Sons A/S.
Abstract: Introduction: Cancer recurrence following orthotopic liver transplantation (OLT) for hepatocellular carcinoma (HCC) is a significant obstacle in up to 10–20% of recipients. Recent evidence suggests that anti-CD3 antibody (OKT3) therapy may be associated with increased rates of HCC recurrence.
Methods: At the University of Colorado Transplant Center, 173 patients underwent OLT for end-stage liver disease with concomitant HCC between 1997 and 2008. Nine clinical and pathologic variables were analyzed to test the association between OKT3 therapy for steroid-resistant rejection (SRR) and HCC recurrence-free survival.
Results: Overall, the rate of HCC recurrence in this cohort was low and comparable across treatment groups (8.7%). Multivariate analysis reveals that increasing tumor diameter and differentiation have a negative impact on HCC recurrence-free survival.
Conclusions: While several pathologic variables appear to influence outcome, we found no association between OKT3 therapy for SRR and HCC recurrence or survival.